Key result
Salvianolic acids offer multi-organ protection against ischemia-reperfusion injury via shared networks and organ-specific adaptations.
Why the study?
Ischemia-reperfusion injury involves multiple organs and complex interconnected pathways, limiting the efficacy of single-target synthetic drugs, and the overall mechanisms and organ-specific signaling pathways of salvianolic acids remain incompletely elucidated.
Salvianolic acids demonstrate potential as a multi-target natural product for treating ischemia-reperfusion injury across various organs.
Answers are grounded in this paper and cite their sources.
Salvianolic acids warrant preclinical-to-clinical translation studies for ischemia-reperfusion injury; leaves open efficacy confirmation before any therapeutic consideration.
Ischemia-reperfusion (I/R) injury poses a significant global health challenge, characterized by multi-organ involvement (such as heart, brain, intestine, and kidneys) and interconnected inflammatory, oxidative, and apoptotic signaling pathways. This complexity limits the efficacy of single-target synthetic drugs. Salvianolic acids (SACs), the major water-soluble components of Salvia miltiorrhiza (SM) with SAC A (Sal A) and SAC B (Sal B) as the predominant constituents, exert multi-organ protective effects through a “one-stone-multiple-birds” strategy. Their core mechanisms encompass a common regulatory network, including inhibition of the nuclear factor kappaB (NF-κB) signaling pathway for anti-inflammatory effects, activation of the nuclear factor erythroid 2-related factor 2/heme oxygenase-1 (Nrf2/HO-1) signaling pathway for anti-oxidative activity, and promotion of the phosphatidylinositol-3 kinase/protein kinase B (PI3K/Akt) signaling pathway for anti-apoptosis. Concurrently, they achieve organ-specific adaptation by targeting distinct pathological features, such as modulating the neuroimmune microenvironment in the brain, optimizing cardiac energy metabolism, preserving renal microvascular integrity, targeting immune cell polarization in the liver, and maintaining intestinal epithelial barrier function and gut microbiota-immune axis homeostasis. However, their overall mechanisms and organ-specific signaling pathways remain incompletely elucidated. Therefore, this review synthesizes recent advances in SACs regarding pharmacology, pharmaceutical foundations, pharmacokinetics (PKs), and quality control. It integrates evidence supporting the “one-stone-multiple-birds” concept, critically examines key pharmaceutical challenges, and highlights future directions. Through the provision of an integrative framework, this work establishes a novel paradigm for developing multi-target natural products and provides essential theoretical support for advancing SACs toward clinical translation as a multi-disease therapeutic strategy.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) conducted a review in Ischemia-reperfusion (I/R) injury. Salvianolic acids (SACs) was evaluated. Salvianolic acids exert multi-organ protective effects against ischemia-reperfusion injury via common regulatory networks and organ-specific adaptations, offering a multi-disease therapeutic strategy.
Synapse has enriched 10 related papers. Consider them for comparative context: